Lenvatinib plus pembrolizumab did not improve overall survival compared to standard of care
Trial shows lenvatinib and pembrolizumab do not improve survival
This Phase 2 randomized trial evaluated lenvatinib and pembrolizumab in 374 adults with recurrent or metastatic head and neck squamous cell …
A Phase 2 trial found that a combination of lenvatinib and pembrolizumab did not improve overall survival for patients with advanced head an…
Chemoimmunotherapy improves objective response rate and survival in advanced pulmonary large-cell neuroendocrine carcinoma
Combining Chemotherapy and Immune Therapy Improves Outcomes for Advanced Lung Cancer
This meta-analysis of 3537 patients with advanced pulmonary large-cell neuroendocrine carcinoma (LCNEC) found that chemoimmunotherapy signif…
Adding an immune-boosting drug to standard chemotherapy helps patients with a specific type of advanced lung cancer live longer.
High tumor mutational burden correlates with improved objective response rate in HNSCC patients
High tumor mutation burden predicts better results in head cancer
This meta-analysis of 1472 patients with head and neck squamous cell carcinoma (HNSCC) found that high tumor mutational burden (TMB) is asso…
A high number of mutations in a tumor may help doctors predict which patients will respond best to immunotherapy.
Comparative Efficacy of Immunotherapy Combinations in Advanced Renal Cell Carcinoma Management
New analysis compares immunotherapy combinations for advanced renal cell carcinoma
A network meta-analysis evaluates diverse immunotherapy combinations for advanced renal cell carcinoma, highlighting specific survival benef…
A large review of over 6,000 patients identifies specific immunotherapy combinations that may improve survival for those with advanced kidne…
First-line immune checkpoint inhibitor therapy improves progression-free survival and overall survival in MSI-H/dMMR mCRC
Immune checkpoint inhibitors improve survival for certain colorectal cancers
This meta-analysis of more than 600 patients with metastatic colorectal cancer (mCRC) involving microsatellite instability-high or mismatch …
New analysis shows immune checkpoint inhibitors offer better survival and fewer side effects than chemotherapy for specific types of metasta…
Gut microbiome taxa and metabolites enhance immune checkpoint inhibitor efficacy and mitigate systemic toxicity
Gut bacteria may improve cancer treatment and reduce side effects
This systematic review examines the role of gut microbiota, including specific taxa like Bacteroides and Akkermansia muciniphila, in modulat…
Specific gut bacteria and their byproducts could help cancer treatments work better while protecting the heart and colon from inflammation.
Immune checkpoint inhibitor regimens for colorectal cancer increase risk of endocrine adverse events
Immunotherapy for colon cancer linked to thyroid problems
This network meta-analysis evaluates endocrine toxicity in patients with colorectal cancer treated with immune checkpoint inhibitor (ICI) ba…
New analysis finds immunotherapy for colorectal cancer raises risk of thyroid issues, especially with certain drug combos.
Adjuvant PD-1 inhibitors significantly improve disease-free survival in patients with resected high-risk muscle-invasive bladder cancer
PD-1 Inhibitors Improve Survival for Muscle Invasive Bladder Cancer
This meta-analysis of Phase 3 trials indicates that adjuvant nivolumab or pembrolizumab improves disease-free survival (DFS) in patients wit…
New data suggests that PD-1 inhibitors like nivolumab or pembrolizumab may improve disease-free survival for patients with high-risk bladder…
Multidimensional models incorporating genomic and microenvironment features likely outperform single-analyte tests to predict immunotherapy response
Multi-Omic Biomarkers May Improve Lung Cancer Treatment Predictions
This narrative review explores the integration of chemokine signatures and multi-omic biomarkers to predict immune checkpoint inhibitor resp…
New research suggests that combining multiple biological markers can better predict how lung cancer patients will respond to immunotherapy.
Novel agent-based regimens provide superior efficacy and lower toxicity than traditional chemotherapy in older adults
New Treatments Show Better Results for Older Adults with Hodgkin Lymphoma
This meta-analysis of 568 patients with classic Hodgkin lymphoma found that novel agent-based regimens, including Brentuximab Vedotin and PD…
Newer treatments like Brentuximab Vedotin and nivolumab show better results and fewer side effects than traditional chemotherapy for older a…
Traditional Chinese medicine may modulate immune resistance barriers in microsatellite-stable colorectal cancer
Traditional Chinese medicine may help some patients with colorectal cancer
This narrative review explores the role of traditional Chinese medicine (TCM) in overcoming immune-resistance mechanisms in patients with mi…
New research explores how traditional herbal medicines might help overcome treatment resistance in a specific type of colorectal cancer.
IO102-IO103 plus pembrolizumab improves progression-free survival in advanced melanoma patients
Trial shows combination therapy may extend time before melanoma progresses
This Phase III randomized controlled trial of 407 patients with untreated advanced melanoma evaluated IO102-IO103 (85 μg) combined with pemb…
A new clinical trial suggests that combining two specific drugs may help patients with advanced melanoma stay stable for longer periods.